Breast Cancer: multiple studies show the CyberKnife System with Synchrony can provide promising results in early-stage patients. Studies evaluating the system found:
Single-dose pre-operative radiation therapy is a feasible, well-tolerated technique with a promising rate of response.
Four-fraction post-lumpectomy stereotactic accelerated partial breast irradiation (S-APBI) is a feasible and reproducible technique. Treatment was well-tolerated and cosmetic outcomes were rated good or excellent by all patients.
Five-fraction S-APBI post-lumpectomy is well-tolerated.

The TomoTherapy® platform pioneered the use of helical radiation delivery and integrated imaging, providing greater control of the radiation dose so it conforms precisely to the tumor and enabling delivery of conventionally fractionated to ultra-hypofractionated treatments.

Innovative Techniques: precise and efficient radiation dose delivery helps make it possible for a wide range of patients to receive treatment, including those with complex indications. Studies undertaken with TomoHelical™ Treatment Delivery demonstrate:
Total marrow irradiation in combination with tandem autologous transplant can provide favorable long-term (10 years) outcomes and toxicity in multiple myeloma patients.
A simultaneous integrated boost and intensity-modulated radiation therapy (IMRT) can offer favorable outcomes and acceptable toxicity in the treatment of anal cancer.
The combination of IMRT and high-dose-rate intra-cavity brachytherapy can provide excellent local control and favorable overall survival for patients with non-metastatic cervical cancer.
Single-fraction lumbopelvic bone irradiation is a promising, very effective treatment option with excellent tolerance rates for patients with multiple painful bone metastases.

Back to HCB News

Rad Oncology Homepage